Lymphoma mantle cell

Lymphomas not included in Working Formulation mycosis fungoides, mantle cell lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT), anaplastic large cell lymphoma, angiocentric lymphoma, angioimmunoblastic lymphadenopathy (AILD), Castleman s disease, adult T-cell leukemia/lymphoma. 

Cladribine -as therapy for low-grade or mantle cell lymphoma... 

Hiddemann, W., Dreyling, M., and Unterhalt, M., Rituximab plus chemotherapy in follicular and mantle cell lymphomas, Semin. Oncol., 30(Suppl. 2), 16-20, 2003. 

Chiarle, R., Budel, L. M., Skolnik, J., Frizzera, G., Chilosi, M., Corato, A., Pizzolo, G., Magidson, J., Montagnoli, A., Pagano, M., et al. (2000). Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95, 619-626. 

Zevalin has been approved by the U S. FDA for radioimmunotherapy in B-cell lymphoma (39). The activity of ibritumomab tiuxetan had been evaluated or is under investigation for rituximab-refractory lymphoma patients, relapsed diffuse large B-cell or mantle cell lymphoma patients, or as a part of high-dose chemotherapy with autologous hematopoietic stem cell support (40). The results of phase I, 11, and randomized trials showed that the single doses of Zevalin are safe and effective in the treatment of patients with relapsed B-cell NHL with a response rate of 60%-80% (40). Unfortunately, no data are available regarding the impact of polymorphisms on the clinical outcomes after Zevalin therapy. 

Southern blotting and polymerase chain reaction are being used for detecting B- and T-cell clonality in lymphoproliferative diseases, including mantle cell lymphoma and lymphoma of the breast (Medeiros and Carr, 1999). Molecular genetic tests are currently important ancillary tools for the diagnosis and classification of malignancy, and their role is likely to increase in the future. 

Brynes, R. K., McCourty, A., Tamayo, R., Jenkins, K., and Battifora, H. 1997. Demonstration of cyclin D1 (Bcl-1) in mantle cell lymphoma Enhanced staining using heat and ultrasound epitope retrieval. Appl. Immunohis-tochem. 5 45 18. 

Vasef, M. A., Medeiros, L. J., Koo, C., McCourty, A., and Brynes, R. K. 1997a Cyclin D1 immunohistochemical staining is useful in distinguishing mantle cell lymphoma from other low-grade B-cell neoplasms in bone marrow. Am. J. Clin. Pathol. 108 302-307. 

A. Boudreau, N. Pennell, D. Combs, and N.L. Berinstein. 2003. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as in vivo purge and consolidative immunotherapy following autologous stem cell transplantation. Aran. Oncol. 14 758—765. 

CLL/SLL, Chronic lymphocytic leukemia/small lymphocytic lymphoma MCL, mantle cell lymphoma FL, follicular lymphoma MZL/MALT, marginal zone lymphoma/mucosa-associated lymphoid tisuse lymphoma SMZL, splenic marginal zone lymphoma HCL, hairy cell leukemia DLCL, diffuse large-cell lymphoma PCM, plasma cell myeloma BCL-1, cyclin D1 FDC MW, Follicular dendritic cell meshworks CK, cytokeratin LELs, lymphoepitheilal lesions. 

Mantle Cell Lymphoma (MCL). Although MCL is considered an indolent lymphoma, the median survival is less than for the other indolent tumors. The disease is primarily nodal however, the peripheral blood is involved in about 25% of cases. The benign counterpart is unknown (S31). 

Mantle cell lymphoma cells are generally small to medium-sized lymphoid cells with variably irregular nuclear contours and a scant amount of cytoplasm. Morphologically, MCL cells can be difficult to distinguish from those of CLL/SLL,... 

D26. Dunphy, C. H., Wheaton, S. E., and Perkins, S. L., CD23 expression in transformed small lymphocytic lymphomas/chronic lymphocytic leukemias and blastic tranformations of mantle cell lymphoma. Mod. Pathol. 10, 818-822 (1997). 

HI8. Hernandez, L., Fest, T., Cazorla, M., Teruya-Feldstein, J., Bosch, F., Peinado, M. A., Piris, M. A., Montserrat, E., Cardesa, A., Jaffe, E. S., Campo, E., and Raffold, M., p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 87,3351-3359 (1996). 

K8. Kilo, M. N., and Dorfman, D. M., The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am. J. Clin. Pathol. 105, 451—457 (1996). 

Singh, N., and Wright, D. H., The value of immunohistochemistry on paraffin wax embedded tissue sections in the differentiation of small lymphocytic and mantle cell lymphomas. J. Clin. Pathol. 50, 16-21 (1997). 

Swerdlow, S. H., Berger, F., Isaacson, P. I., and Muller-Hermelink, H. K., Mantle cell lymphoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (R. S. Jaffe, N. L. Harris, H. Stein, and J. W. Vardiman, eds.), pp. 168-170. IARC Press, Lyon, 2001. 

Swerdlow, S. H., Yang, W. I., Zukerberg, L. R., Harris, N. L., Arnold, A., and Williams, M. E., Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCLl/cyclin D1 gene. Hum. Pathol. 26, 999-1004 (1995). 

Another small-molecule pan-Bcl-2 inhibitor that mimicks BH3-only proteins, GX15-070 (developed by GeminX, Montreal, Canada) (Fig. 3k), was shown to be a potent apoptosis inducer in breast cancer, chronic lymphocytic leukemia, multiple myeloma, and mantle cell lymphoma cell lines (76-79). 

Campas C, et al. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp. Hematol. 2006 34 1663-1669. Perez-Galan P, et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007 109 4441-4449. 

---